Reading basis: Based on the full editorial by Stefan Toggweiler and Mathias Wolfrum. This is commentary on research, not a new clinical trial.
Who is offering this perspective?
Stefan Toggweiler and Mathias Wolfrum, from Heart Center Lucerne in Switzerland, discuss the Zhang et al. PFO trial. Their article is an editorial commentary published in Cardiovascular Diagnosis and Therapy, rather than a paper authored by the Fuwai trial team. [1]
- 01
Original study
What did the investigators measure and report?
- 02
Editorial perspective
What do the commentators find convincing or uncertain?
- 03
Open question
Which proposed benefit still needs investigation?
An editorial discusses evidence; it does not add a new randomized patient group. Source 1
What do they find encouraging?
The editorial recognizes the randomized comparison and two-year follow-up as useful evidence. It also discusses the possibility that resorbable technology could make future access across the atrial septum easier. The authors describe that potential benefit as something requiring demonstration. [1]
Where do they urge caution?
The authors emphasize that a modest trial cannot reliably exclude rare complications. They call for longer follow-up, multicenter registry data, rhythm monitoring and closer study of operator experience. Their conclusion does not establish bioresorbable closure as a replacement standard for all patients. [1]
How we suggest using an editorial
Our reading approach is to keep three questions separate: what the trial observed, what the commentators infer, and what future studies might establish. An editorial helps identify uncertainties; it is not a personalized treatment recommendation. If a proposed advantage matters to you, ask your doctor whether it has been measured or is still a research question.
- Which proposed benefits have been demonstrated in people?
- What is known about outcomes beyond the reported follow-up?
- What experience does the treating team have with the specific device?
Where to read the original
Toggweiler S, Wolfrum M. Bioresorbable patent foramen ovale closure—is less more? Cardiovasc Diagn Ther. 2026;16(4):58. DOI: 10.21037/cdt-2026-0209.
Original publication ↗
This original reading note is prepared for the China Hospital Access website. It is not authored or endorsed by the researchers, and is not a reproduction of their publication. It provides general information, not an individual medical assessment.